Pharma's Almanac TV
PA TV
Your Name
Your Email
Manage Account
Dashboard
Sign Out
Sign In
Register
Topics
Products
ADC
API - Small Molecule
Biologics
Biopharmaceuticals
Biosimilars
Cell and Gene Therapy
DNA
Drug Product
Drug Substance
Equipment
Generics
Immunotherapy
Injectables
Monoclonal Antibody
Novel Therapeutics
Oral Solid Dosage
Orphan Drugs
Parenterals
Stem Cells
Vaccine
Services
Big Data
Bioprocessing
Clinical Trials
Continuous Manufacturing
Diagnostics
Drug Delivery
Drug Development
Drug Discovery
Facility
Formulation
Innovation
Oncology
Patient Adherence
Patient Centric
Preclinical
Process Development
Quality
Regulatory
Research
Serialization
Segment
Biomanufacturing
Biotechnology
CDMO
Consulting
CRO
Engineering
Equipment
Excipients
Healthcare
Intermediates
Logistics
Manufacturing
Packaging
Supply Chain
Business
Agreement
Appointment
Business
Capacity Expansion
Collaboration
Growth
Investment
Licensing
M&A
Market Expansion
Market Intelligence
Market Prediction
New Facility
Strategic Partnership
Analytics
Research
CDMO
CRO
Excipients
Pharmaceutical Equipment
Pharmaceutical Intermediates
Supply Chain Logistics
Magazine
Current Issue
Archive
Community
Company A to Z
Content Filter
More+
Staffing
Media Kit
Membership Levels
By The Numbers
Drug Development
528 Articles Available
1
22
Can't find what you're looking for? Try our
advanced search
.
Funding
Startup Gets Significant Funding to Support Novel Biosensing Technology
PAO-M11-19-NI-004
RNA
RNA Repressor Switches Off Protein Production
PAO-M11-19-NI-001
Commercial Agreement
Dicerna™ Enters Agreement with Roche to Develop and Commercialize DCR-HBVS for the Treatment of Chronic Hepatitis B Virus (HBV) Infection
PR-M10-19-NI-050
Vaccine
GSK Candidate Vaccine Demonstrates Sustained Level of Protection Against Active Pulmonary Tuberculosis
PR-M10-19-NI-040
Containment
Meeting the Need for Higher Containment
PAP-Q3-19-CL-025
Gut–Brain Axis
Harnessing the Gut–Brain Axis to Treat Neurological Disorders
PAP-Q3-19-CL-003
Migraine Therapy
Mimicking Environmental Enrichment for Migraine Therapy
PAP-Q3-19-CL-026
Cannabinoids
Leveraging Biosynthetic Expertise to Access a Wide Portfolio of Cannabinoids
PAP-Q3-19-CL-031
Drug Development
Looking Beyond Current Treatments for CNS Diseases and Disorders
PAP-Q3-19-CL-036
Tumor Microenvironment
Focusing on the Tumor Microenvironment Leads to Novel Drug Targets
PAP-Q3-19-CL-023
Diabetes Prevention
Sigrid Therapeutics Takes Another Step Towards a Treatment for Prevention of Type 2 Diabetes
PR-M10-19-NI-032
Portfolio Update
Syros Announces Update on Selective CDK7 Inhibitor Portfolio
PR-M10-19-NI-026
FDA Priority Review
[Fam-] Trastuzumab Deruxtecan Granted FDA Priority Review for Treatment of Patients With HER2-positive Metastatic Breast Cancer
PR-M10-19-NI-025
Boehringer Ingelheim Partners with Inflammasome Therapeutics to Develop Novel Therapies for Patients with Retinal Disease
PR-M09-19-NI-050
Patient Centricity
Astellas Takes Patient Centricity to the Next Level
PAO-M09-19-NI-019
Clinical Trial
Arial Halts Trial for First Drug to Treat DRP Early
PAO-M09-19-NI-015
Clinical Trials
ACADIA Pharmaceuticals Announces Meets the Primary Phase 3 Endpoint in Patients with Dementia-Related Psychosis
PR-M09-19-NI-036
FDA Clearance
New Vision System for Tracking Eye Movement Gets FDA Clearance
PAO-M09-19-NI-014
Competition
Current Players Could Face Competition in the PCSK9 Space
PAO-M09-19-NI-010
Financing
Pharvaris Announces $66 Million Series B Financing to Advance the Clinical Development of an Oral Therapy for Hereditary Angioedema
PR-M09-19-NI-029
Vaccine
Pfizer Announces Positive Preliminary Results from a 2 Study of its 20-Valent Pneumococcal Conjugate Vaccine Candidate for Disease Prevention in Infants
PR-M09-19-NI-028
Zika
Batavia Biosciences to Deploy Horizon Discovery’s CHO Cell Technology to Develop Anti-Zika Biotherapeutic
PR-M09-19-NI-019
Peptide Hydrogel
Peptide Hydrogels Could Help Heal Traumatic Brain Injuries
PR-M09-19-NI-014
Clinical Data
Concert Pharmaceuticals Reports Positive CTP-543 Results from Phase 2 Alopecia Areata Trial
PR-M09-19-NI-010
1
22
»
